References
- Fiqueiró-Filho EA, Oliveira ML, Pompilio MA, et al. Obstetric, clinical, and perinatal implications of H1N1 viral infection during pregnancy. Int J Gynaecol Obstet 2012;116:214–8
- Lenzi L, Pontarolo R. Evaluation of pregnancy as a risk factor in the outcomes of influenza A (H1N1)/2009 in women of childbearing age. Cad Saude Publica 2012;28:395–9
- Lee BY, Bailey RR, Wiringa AE, et al. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstet Gynecol 2009;114:971–80
- He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999;37:471–84
- Ariano RE, Sitar DS, Zelenitsky SA, et al. Enteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza. CMAJ 2010;182:357–63
- Wattanagoon Y, Stepniewska K, Lindegardh N, et al. Pharmacokinetics of high-dose oseltamivir in healthy volunteers. Antimicrob Agents Chemother 2009;53:945–52
- Widmer N, Meylan P, Ivanyuk A, et al. Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics. Clin Pharmacokinet 2010;49:741–65
- Greer LG, Leff RD, Rogers VL, et al. Pharmacokinetics of oseltamivir according to trimester of pregnancy. Am J Obstet Gynecol 2011;204:S89–93
- Beigi RH, Han K, Venkataramanan R, et al. Pharmacokinetics of oseltamivir among pregnant and nonpregnant women. Am J Obstet Gynecol 2011;204:S84–8
- Hutson JR, Garcia-Bournissen F, Davis A, et al. The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs. Clin Pharmacol Ther 2011;90:67–76
- Kovo M, Haroutiunian S, Feldman N, et al. Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol 2008;136:29–33
- Peytavin G, Leng JJ, Forestier F, et al. Placental transfer of pyrimethamine studied in an ex vivo placental perfusion model. Biol Neonate 2000;78:83–5
- Mathiesen L, Mose T, Morck TJ, et al. Quality assessment of a placental perfusion protocol. Reprod Toxicol 2010;30:138–46
- Mathiesen L, Rytting E, Mose T, et al. Transport of benzo[α]pyrene in the dually perfused human placenta perfusion model: effect of albumin in the perfusion medium. Basic Clin Pharmacol Toxicol 2009;105:181–7
- Berveiller P, Mir O, Vinot C, et al. Transplacental transfer of oseltamivir and its metabolite using the human perfused placental cotyledon model. Am J Obstet Gynecol 2012;206:92.e1–6
- Worley KC, Roberts SW, Bawdon RE. The metabolism and transplacental transfer of oseltamivir in the ex vivo human model. Infect Dis Obstet Gynecol 2008;2008:927574
- Nanovskaya TN, Patrikeeva S, Zhan Y, et al. Transplacental transfer of oseltamivir carboxylate. J Matern-Fetal Neo M 2012;25:2312–5
- Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003;55:3–29
- Oqihara T, Kano T, Wagatsuma T, et al. Oseltamivir (tamiflu) is a substrate of peptide transporter 1. Drug Metab Dispos 2009;37:1676–81
- Meijer WJ, Bruinse HW, van den Broek MP, et al. Oseltamivir and its active metabolite cross the placenta at significant levels. Clin Infect Dis 2012;54:1676–7
- Donner B, Niranjan V, Hoffmann G. Safety of oseltamivir in pregnancy: a review of preclinical and clinical data. Drug Saf 2010;33:631–42
- Lieberman RW, Bagdasarian N, Thomas D, et al. Seasonal influenza A (H1N1) infection in early pregnancy and second trimester fetal demise. Emerg Infect Dis 2011;17:107–9